Enhancing ADC Development with Anti-MMAE Antibodies

Monomethyl auristatin E (MMAE), a potent mitotic inhibitor derived from dolastatin 10, plays a pivotal role in antibody-drug conjugates (ADCs) for cancer therapy. ADCs precisely target cancer cells, minimizing collateral damage. However, ADC development requires thorough pharmacokinetic and safety assessments. Our specialized anti-MMAE antibodies streamline this process, facilitating PK analysis and safety evaluation. These antibodies are crucial tools for optimizing ADCs, ensuring their effectiveness and safety in revolutionizing cancer treatment.

We invite you to explore the cutting-edge world of anti-MMAE antibodies by requesting a complimentary sample. Experience the exceptional quality and potential of our antibodies, enabling you to elevate your research to new heights. Simply fill out the form below, and we’ll send you a sample to kickstart your innovative projects. Take the first step towards groundbreaking discoveries with our Anti-MMAE antibodies – it’s just a click away!

Please enable JavaScript in your browser to complete this form.

Name *

First

Last

Email *

What is your estimated annual demand for anti-Payload antibodies? *

To which antibodies are you interested in? (Multiple selections allowed) *

• Anti-payload Antibodies
• Anti-BMK Antibodies
• BMK Antibodies
• Human/cyno Cross-reactive Antibodies
• Humanized Antibodies

Besides the anti-MMAE antibody, will you be interested in any of the following anti-payload antibodies? *

• Anti-PBD Antibodies
• Anti-Dxd Antibodies
• Anti-SN-38 Antibodiese
• Anti-DM-1 Antibodies
• Anti-DM-4 Antibodies

Which of DIMA's products & Services from the following list are you interested in trying for your work? *

• Purified Bioactive Recombinant Proteins
• Lead mAbs for Drug Targets
• Prevalidated B Cell Libraries for Quick Screening of Lead mAbs
• Reagents to Validate Antibody Internalization
• Mammalian Display Based Antibody Engineering Platform for Humanization, Affinity Maturation and PTM removal
• None of above

Do you need someone from DIMA to contact you for your special requirements? *Yes, please contact me.Not at the moment, maybe laterNot at all

Research Area

• Antibody Therapies
• Cell Therapies
• Gene Therapies
• Diagnostics
• Small Molecule Therapies
• Others

Your Message

DIMA Biotech values your privacy. Your personal information will solely be used for account administration and the services you've requested. Occasionally, we may contact you about our products and content aligned with your interests. Please let us know your preferences below: *

• I consent to receiving additional communications from DIMA Biotech.

You have the freedom to opt out of these communications at any time. For guidance on unsubscribing, to gain insights into our privacy practices, and to understand our unwavering commitment to protecting your privacy, kindly consult our Privacy Policy. By clicking 'submit' below, you grant DIMA Biotech permission to store and process the personal information you've provided above, solely for the purpose of delivering the requested content.

Submit Your Request

Terms and Conditions:

• Offer available to direct customers on a first-come, first-served basis.
• Multiple submissions from the same research team will not be considered.
• DIMA Biotech Co., Ltd reserves the right to reject or terminate orders.
• Offer cannot be combined with other promotions.
• Void where prohibited by law or institutional policy.
• Feedback on trial results required within one month.
• Offer ends on 12/31/2023.

View All Anti-MMAE Antibodies